Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.

ABSTRACT:

Background

Glioblastoma patients are still not cured by the treatments available at the moment. We investigated the therapeutic properties of temozolomide in combination with F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16, specific to the A1 domain of tenascin-C.

Methods

We conducted three preclinical therapy studies, using subcutaneous and intracranial U87MG glioblastoma tumours xenografted in BALB/c nude mice. The same therapeutic schedule was used, consisting of five total administrations every third day, of 0.525 mg temozolomide, 20 microg F16-IL2, the combination, or the control solution.

Results

Immunohistochemical analysis of U87MG xenografts and of human glioblastoma specimens showed selective tu

SUBMITTER: Pedretti M 

PROVIDER: S-EPMC2966626 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature